bioRxiv · 10.1101/119693
Can Human Embryonic Stem Cell-Derived Stromal Cells Serve A Starting Material For Myoblasts?
Abstract
A large number of myocytes is necessary to treat intractable muscular disorders such as Duchenne muscular dystrophy with cell-based therapies. However, starting materials for cellular therapy products such as myoblasts, marrow stromal cells, menstrual blood-derived cells and placenta-derived cells have a limited lifespan and cease to proliferate in vitro. From the viewpoints of manufacturing and quality control, cells with a long lifespan are more suitable as a starting material. In this study, we generated stromal cells for future myoblast therapy from a working cell bank of human embryonic stem cells (ESCs). The ESC-derived CD105+ cells with extensive in vitro proliferation capability exhibited myogenesis and genetic stability in vitro. These results imply that ESC-derived CD105+ cells are another cell source for myoblasts in cell-based therapy for patients with genetic muscular disorders. Since ESCs are immortal, mesenchymal stromal cells generated from ESCs can be manufactured at a large scale in one lot for pharmaceutical purposes.
Source connections
Explore related subjects
Keep this discovery
Ando, Y., Saito, M., Machida, M., Noro, C., Takahashi, M., Toyoda, M., Umezawa, A.. 2017-03-23. Can Human Embryonic Stem Cell-Derived Stromal Cells Serve A Starting Material For Myoblasts?. https://doi.org/10.1101/119693
Cite the original work for its findings. Save a collection to share your selection of sources.